Open Access
Open access
American Society of Clinical Oncology (ASCO)
JCO Global Oncology
,  volume 11 ,  issue 11

Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort

Ullas Batra 1
, 
Kumar Prabhash 2
, 
Vanita Noronha 2
, 
Ramakant Deshpande 3
, 
Sachin Khurana 4
, 
Gull Mohammad Bhat 5
, 
Rajesh Mistry 6
, 
Vivek Agarwala 7
, 
Sajjan Rajpurohit 8
, 
Bhavesh Poladia 9
, 
Manasi Sharma 10
, 
Saquib Zaffar Banday 11
1
 
2
 
3
 
Asian Cancer Institute, Mumbai, India | 
4
 
Department of Medical Oncology, AIIMS New Delhi, Delhi, India | 
5
 
Medical Oncology, National Institute for Medical Science and Research, Jaipur, India | 
6
 
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India | 
7
 
Department of Medical Oncology and Haemato-Oncology, Narayana Superspeciality Hospital, Howrah, India | 
8
 
Max Super Speciality Hospital, Shalimar Bagh, India | 
9
 
Medical Oncology, Thangam Cancer Center, Thangam Hospital, Namakkal, India | 
10
 
11
 
Medical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India | 
Publication type: Journal Article
Publication date: 2025-01-07
American Society of Clinical Oncology (ASCO)
scimago Q2
wos Q2
SJR: 1.207
CiteScore: 5.0
Impact factor: 3.0
ISSN: 26878941
DOI:  10.1200/go-24-00353
PubMed ID:  39772802
Abstract
PURPOSE

The spectrum of EGFR is inadequately researched in patients with early-stage non–small cell lung cancer (NSCLC) in India. EARLY-epidermal growth factor receptor (EGFR) India (ClinicalTrials.gov identifier: NCT04742192 ), as part of a noninterventional, real-world global study, evaluated the prevalence of EGFR mutations in early-stage NSCLC in India.

METHODS

Prospective data from adult patients with surgically resected stage IA to IIIB (American Joint Committee on Cancer eighth edition) NSCLC between March 2021 and October 2022 were analyzed. In addition to descriptive statistics, Fisher's exact test with Monte Carlo was used to determine the association between EGFR mutations and clinicodemographic parameters.

RESULTS

Of 74 patients (median age, 57.0 [range, 33.0-77.0] years) enrolled from eight centers in India, 73.0% (54 of 74) were males, 56.1% (37 of 66) were nonsmokers, and 95.9% (71 of 74) had adenocarcinoma. The EGFR mutation prevalence was 26.0% (19 of 73), of which Exon-19 deletions were the predominant subtype (13, 68.4%) followed by Exon 21-L858R (4, 21.1%), Exon 20-T790M (1, 5.3%), and compound (1, 5.3%) mutations. Nearly half (48.6%, 36 of 74) of the patients underwent only surgical resection. The remaining 51.4% (38 of 74) of the patients were prescribed neoadjuvant (n = 12; 16.2%) and adjuvant (n = 31; 41.9%) systemic therapies, and one patient (1.4%) received radiotherapy along with systemic therapy. In 60 patients with stage IB to IIIB NSCLC, systemic therapies, mainly platinum-based chemotherapy, were prescribed in 36 (60.0%). Only 8.1% (6 of 74) of the patients were prescribed EGFR-tyrosine kinase inhibitor (TKI), of which two received neoadjuvant and four were planned for adjuvant EGFR-TKI. Two (2.7%) patients were prescribed adjuvant immunotherapy. The univariate analysis showed higher odds of EGFR mutation for females (odds ratio, 3.96; P = .017).

CONCLUSION

EARLY-EGFR India results showed the prevalence of EGFR mutation to be 26%. The study emphasized the pressing need for up-front biomarker testing at diagnosis to ensure optimal and timely personalized treatment.

Found 
Found 

Top-30

Journals

1
Translational Lung Cancer Research
Translational Lung Cancer Research, 1, 100%
Translational Lung Cancer Research
1 publication, 100%
1

Publishers

1
AME Publishing Company
AME Publishing Company, 1, 100%
AME Publishing Company
1 publication, 100%
1
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
1
Share
Cite this
GOST |
Cite this
GOST Copy
Batra U. et al. Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort // JCO Global Oncology. 2025. Vol. 11. No. 11.
GOST all authors (up to 50) Copy
Batra U., Prabhash K., Noronha V., Deshpande R., Khurana S., Bhat G. M., Mistry R., Agarwala V., Rajpurohit S., Poladia B., Sharma M., Banday S. Z. Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort // JCO Global Oncology. 2025. Vol. 11. No. 11.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1200/go-24-00353
UR - https://ascopubs.org/doi/10.1200/GO-24-00353
TI - Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort
T2 - JCO Global Oncology
AU - Batra, Ullas
AU - Prabhash, Kumar
AU - Noronha, Vanita
AU - Deshpande, Ramakant
AU - Khurana, Sachin
AU - Bhat, Gull Mohammad
AU - Mistry, Rajesh
AU - Agarwala, Vivek
AU - Rajpurohit, Sajjan
AU - Poladia, Bhavesh
AU - Sharma, Manasi
AU - Banday, Saquib Zaffar
PY - 2025
DA - 2025/01/07
PB - American Society of Clinical Oncology (ASCO)
IS - 11
VL - 11
PMID - 39772802
SN - 2687-8941
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Batra,
author = {Ullas Batra and Kumar Prabhash and Vanita Noronha and Ramakant Deshpande and Sachin Khurana and Gull Mohammad Bhat and Rajesh Mistry and Vivek Agarwala and Sajjan Rajpurohit and Bhavesh Poladia and Manasi Sharma and Saquib Zaffar Banday},
title = {Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort},
journal = {JCO Global Oncology},
year = {2025},
volume = {11},
publisher = {American Society of Clinical Oncology (ASCO)},
month = {jan},
url = {https://ascopubs.org/doi/10.1200/GO-24-00353},
number = {11},
doi = {10.1200/go-24-00353}
}